ImmuneWalk
Immunewalk is a clinical-stage biopharmaceutical company developing novel therapies for immune inflammatory indications. Its lead candidate, IW-601, is a proprietary monoclonal antibody engineered to prevent monocytes and neutrophils from entering inflamed tissues via a newly discovered adhesion checkpoint. The company expects Phase 1b data in the first half of 2027 and a Phase 2 launch in the second half of 2027.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Funding
Founders
Product
Problem
Current anti-inflammatory therapies do not specifically block the early migration of key immune cells into inflamed tissues, limiting efficacy across a range of immune-mediated inflammatory diseases. This leaves patients with suboptimal treatment options, particularly for conditions where monocyte and neutrophil infiltration drives disease progression.
Solution
Immunewalk is developing novel therapies targeting a newly discovered adhesion checkpoint that controls the ability of certain immune cells to reach inflamed tissues. The company's lead clinical-stage candidate, IW-601, is a proprietary monoclonal antibody engineered to specifically prevent monocytes and neutrophils from entering inflamed sites. By blocking this adhesion mechanism, IW-601 offers a differentiated approach compared to existing anti-inflammatory agents, potentially addressing both highly prevalent and rare inflammatory indications. The therapy is designed to intervene upstream of tissue damage, offering a novel mechanism of action in the immunology landscape.
Target Audience
Primary customers are patients with immune-mediated inflammatory diseases, and the company's clinical partners include healthcare providers and research institutions specializing in inflammatory indications.
Features
- Lead candidate IW-601 is a proprietary monoclonal antibody specifically engineered to block monocyte and neutrophil migration into inflamed tissues
- Targets a newly discovered adhesion checkpoint that controls immune cell access to inflamed sites
- Differentiated mechanism of action compared to current anti-inflammatory agents
- Potential applicability across both highly prevalent and rare inflammatory indications
- Clinical-stage pipeline with Phase 1b data expected in the first half of 2027 and Phase 2 launch anticipated in the second half of 2027